Boston Scientific agreed to sell its BTG Specialty Pharmaceuticals for $800 million cash to affiliates of the Brussels drugmaker Serb SAS.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 30) * Amicus Therapeutics, Inc. (NASDAQ: FOLD) * Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) * argenx SE - ADR (NASDAQ: ARGX) * Beam Therapeutics Inc (NASDAQ: BEAM) * Bioanalytical Systems, Inc. (NASDAQ: BASI) * BioLife Solutions Inc (NASDAQ: BLFS) * BioNTech SE - ADR (NASDAQ: BNTX) (reacted to reports of imminent approval for its coronavirus vaccine candidate in the U.K.) * BioTelemetry Inc (NASDAQ: BEAT) * Blueprint Medicines Corp (NASDAQ: BPMC) * BridgeBio Pharma Inc (NASDAQ: BBIO) * Cardiff Oncology Inc (NASDAQ: CRDF) * Cellectis SA (NASDAQ: CLLS) * Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) * Chimerix Inc (NASDAQ: CMRX) * China Biologic Products Holdings Inc (NASDAQ: CBPO) * Crispr Therapeutics AG (NASDAQ: CRSP) * CureVac BV (NASDAQ: CVAC) (announced third-quarter results and plans to initiate Phase 2b/3 study of its coronavirus vaccine candidate) * Eidos Therapeutics Inc (NASDAQ: EIDX) * Fate Therapeutics Inc (NASDAQ: FATE) * Foghorn Therapeutics Inc. (NASDAQ: FHTX) * Generation Bio Co (NASDAQ: GBIO) * Inhibrx Inc (NASDAQ: INBX) * Inspire Medical Systems Inc (NYSE: INSP) * Intellia Therapeutics Inc (NASDAQ: NTLA) * Mersana Therapeutics Inc (NASDAQ: MRSN) (announced the appointment of a new chief medical officer) * Moderna Inc (NASDAQ: MRNA) (announced positive efficacy and safety data from Phase 3 study of coronavirus vaccine candidate and filing for emergency use authorization) * Myovant Sciences Ltd (NYSE: MYOV) * NeoGenomics, Inc. (NASDAQ: NEO) * Neuronetics Inc (NASDAQ: STIM) * Nurix Therapeutics Inc (NASDAQ: NRIX) * Ocular Therapeutix Inc (NASDAQ: OCUL) * Oncorus Inc (NASDAQ: ONCR) * Praxis Precision Medicines Inc (NASDAQ: PRAX) * Pulmonx Corp (NASDAQ: LUNG) * Spero Therapeutics Inc (NASDAQ: SPRO) * Stoke Therapeutics Inc (NASDAQ: STOK) * Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP) * TRACON Pharmaceuticals Inc (NASDAQ: TCON) * Trillium Therapeutics Inc (NASDAQ: TRIL) * Trinity Biotech plc (NASDAQ: TRIB) * Veracyte Inc (NASDAQ: VCYT) * Zai Lab Ltd - ADR (NASDAQ: ZLAB)None of the NYSE or Nasdaq-listed biopharma stocks and medical device manufacturers hit fresh 52-week highs Nov. 30.Stocks In Focus Amarin Accuses Hikma Of Infringing Vascepa Patents Amarin Corporation plc (NASDAQ: AMRN) said it has filed a patent infringement lawsuit against Hikma Pharma and Hikma's U.S. affiliate, alleging Hikma has infringed on certain patents related to its Vascepa by selling and importing icosapent ethyl capsules in or into the U.S.The lawsuit was filed in the U.S. District Court in Delaware."The Amarin complaint details its position that Hikma has knowingly and willfully introduced its generic product in a manner that infringes Amarin's patent rights and has exceeded the scope of permitted Hikma activity," Amarin said.Amarin shares were up 4.44% at $5.18 premarket Tuesday. Pfizer, BioNTech Files Marketing Authorization Application For Coronavirus Vaccine Candidate In Europe Pfizer Inc. (NYSE: PFE) and its partner BioNTech announced the submission Monday of a formal application for Conditional Marketing Authorization to the European Medicines Agency for BNT162b2, the companies' investigational vaccine against SARS-CoV-2.The companies said the submission completes the rolling review process initiated on Oct. 6.In premarket trading Tuesday, Pfizer shares were rising 2.27% to $39.18 and BioNTech shares were down 0.88% at $123.15. MacroGenics Strikes Commercialization Partnership For Cancer Drug Ahead of Approval MacroGenics Inc (NASDAQ: MGNX) said it has partnered with Eversana, a commercial services company to the global life sciences industry, to commercialize margetuximab in the U.S. if it is approved.Maegetuximab has a PDUFA action date of Dec. 16, by which time the FDA will decide whether to approve the monoclonal antibody for the treatment of breast cancer.Under the agreement, Eversana stands to receive a co-exclusive right to conduct approved commercialization activities for which it will be compensated with the right to earn future revenue share payments that are capped at 125% of Eversana's cumulative service fees, MacroGenics said.Entera Bio Appoints Biopharma Industry Veteran As CEO Entera Bio Ltd (NASDAQ: ENTX) said its board has appointed Spiros Jamas to the role of CEO and as a member of the board effective Jan. 4, 2021. Jamas will succeed Dr. Roger Garceau, who has been serving as interim CEO since August. "Spiros Jamas is a biotech entrepreneur with over 30 years of senior management experience in the biopharmaceutical industry," Entera Bio said.The stock was up 1.62% to $1.25 in after-hours trading.Related Link: The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions NuCana's Chemo Combo Found More Effective Than Standard-Of-Care In Early Stage Study NuCana PLC (NASDAQ: NCNA) announced publication in the online edition of The Oncologist final results of the Phase 1b study of Acelarin plus cisplatin for patients with advanced biliary tract cancer, confirming a high objective response rate and favorable safety profile.The ORR for the Acelarin plus cisplatin was 44% compared to the 26% ORR for Eli Lilly And Co's (NYSE: LLY) gemcitabine plus cisplatin."We are very encouraged by the final efficacy and safety data from ABC-08", said Hugh Griffith, NuCana's CEO."We are committed to developing Acelarin plus cisplatin as the first approved front-line treatment for patients with advanced biliary tract cancer."The stock gained 12.06% to $5.11 in after-hours trading.Galapagos Reports Positive Proof-Of-Concept Topline Data For Idiopathic Pulmonary Fibrosis Drug Galapagos ADR Representing Ord Shs (NASDAQ: GLPG) announced positive topline results for its investigational GPR84 antagonist GLPG1205 in a proof-of-concept Phase 2 trial in idiopathic pulmonary fibrosis patients.The company said it plans to advance the investigational asset into a dose-finding Phase 2b study.Boston Scientific To Divest BTG Specialty Pharma Business For $800M In Cash Boston Scientific Corporation (NYSE: BSX) said it has entered into a definitive agreement with SERB, a European specialty pharmaceutical group, to sell its BTG Specialty Pharmaceuticals business for $800 million in cash.SERB, backed by private equity firm Charterhouse Capital Partners, owns a diversified portfolio of prescription medicines focused on rare and life-threatening diseases, Boston Scientific said.The transaction is expected to close in the first half of 2021, subject to customary regulatory approvals and other closing conditions.Offerings Intellia Therapeutics Inc (NASDAQ: NTLA) said it has commenced an underwritten public offering of $150 million of shares of its common stock. All of the shares in the proposed offering are to be sold by Intellia.The stock slid 3.23% at $38 premarket Tuesday. Cogent Biosciences Inc (NASDAQ: COGT) said it has commenced an underwritten public offering of $60 million in shares of its common stock. All the shares are being sold by the company.The stock was down 13.35% premarket at $8.50.On The Radar PDUFA Dates The FDA will decide on Vanda Pharmaceuticals Inc.'s (NASDAQ: VNDA) sNDA for Hetlioz capsules and its NDA for the liquid formulation of Hetlioz for the treatment of adults and children, respectively, with Smith-Magenis Syndrome.Related Link: Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates See more from Benzinga * Click here for options trades from Benzinga * The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions * Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Boston Scientific Corp. said Tuesday it is selling its BTG Specialty Pharmaceuticals business to Stark International Lux S.A.R.L. and SERB SAS, both affiliates of specialty pharma group SERB, for $800 million in cash. SERB is backed by private-equity firm Charterhouse Capital Partners and owns a portfolio of prescription drugs focused on rare and life-threatening diseases. "After acquiring BTG in 2019 for approximately $3.7 billion net of cash on hand, and following the close of this transaction, we will have divested the two BTG non-medical device portions -- Pharmaceutical Licensing royalties in the fourth quarter of 2019 and Specialty Pharmaceuticals announced today -- for more than $1.0 billion in net proceeds," said Jeff Mirviss, executive vice president and president, Peripheral Interventions, Boston Scientific. "We continue to be very pleased with the performance of the core Interventional Medicines business, the primary driver of the BTG acquisition, which has delivered strong growth and is expected to exceed our original goal of $175 million in synergies." The agreement includes the transfer of about 280 employees and five facilities with the deal expected to close in the first half of 2021. Boston Scientific shares rose 0.9% premarket but have fallen 26.7% in the year to date, while the S&P 500 has gained 12%.